We also have knowledge and expertise in the formulation development of modified or targeted release within the body. A comprehensive selection of supporting technologies underpins our professional expertise, and all prototype formulations undergo extensive screening and stability evaluation in a non-GMP environment.
Once Quay Pharma has investigated the fundamental properties of a drug, we can prepare a formulation development strategy to bring it rapidly and effectively to First in Human (FIH) studies and on towards clinical use.
The formulations we create are designed to match our clients’ requirements and resources precisely. Significantly, they are provided royalty-free, so there is no commitment or limiting factor on any future development.
Our work is carried out on a purely fee-for-service basis, with our aim to provide the best formulation development and the best chance of clinical success. An extensive suite of formulation development services is offered at Quay Pharma.